RecruitingNot ApplicableNCT06515093

Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC

A Randomized Post-Market Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating Diabetic Foot Ulcers (DFU) and SanoGraft® in Treating Venous Leg Ulcers (VLU) to SOC Treatment

Sponsor

Surgenex

Enrollment

180 participants

Start Date

Jun 23, 2024

Study Type

INTERVENTIONAL

Conditions

Diabetic Foot Ulcer Venous Leg Ulcer

Summary

The purpose of this study is to compare Pellograft to standard of care modalities in treating diabetic foot ulcers in human subjects, and to compare Sanograft to standard of care in treating venous leg ulcers. The study will demonstrate wound healing outcomes with comparators including time to wound epithelialization, decrease in wound size, and total number of study product applications towards healing outcome. This information is important to the Centers for Medicare and Medicaid Services (CMS) and other payors in determining coverage policy and reimbursement for this product category.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

Subject is at least 18 years of age
Diabetic Foot Ulcer Only - Subject has diagnosed Type 1 or Type 2 diabetes
Subject's wound is located on foot or ankle (DFU) or leg (VLU)
Subject has diabetic foot ulcer \> 1.0 cm2 and ≤ 25 cm2 OR venous leg ulcer \> 1.0 cm2 and ≤ 50 cm2
Subject has adequate circulation to affected extremity with TcPO2 results of ≥ 40 mm Hg on the dorsum of the affected foot or ABI results ≥ 0.7 and≤ 1.2 or Great Toe Pressure ≥ 50 mmHg
Subject is willing and able to comply with all protocol requirements
Subject is willing and able to provide informed consent or obtain consent from legal authorized representative (LAR)

Exclusion Criteria11

Subject is pregnant
Subject with diagnosed diabetes has HbA1C \> 12 within 3 months Prior to randomization
Subject has \> 30% reduction in wound size after 2-week run-in period
Subject has active infection, undrained abscess, or critical colonization of the wound with bacteria
Subject has osteomyelitis or joint capsule on investigator's exam or radiographic evidence or bone culture, histology, x-ray changes or MRI
Subject is on parenteral corticosteroids or any cytotoxic agents for 7 consecutive days during 30 days before screening. Chronic oral steroid use is not excluded if dose \< 10 mg per day of prednisone
Subject is currently undergoing cancer treatment
Subject has used biologic skin substitutes within 14 days of enrollment
Subject has an allergy to suture material
Subject has life expectancy less than six-months as assessed by the investigator
Subject is participating in another clinical research study prior to this study completion

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.